Loading…

GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma

BackgroundA better understanding of the molecular mechanisms that manifest in the immunosuppressive tumor microenvironment (TME) is crucial for developing more efficacious immunotherapies for hepatocellular carcinoma (HCC), which has a poor response to current immunotherapies. Regulatory T (Treg) ce...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2021-09, Vol.9 (9), p.e002787
Main Authors: Wang, Zhaowei, He, Lei, Li, Weina, Xu, Chuanyang, Zhang, Jieyu, Wang, Desheng, Dou, Kefeng, Zhuang, Ran, Jin, Boquan, Zhang, Wei, Hao, Qiang, Zhang, Kuo, Zhang, Wangqian, Wang, Shuning, Gao, Yuan, Gu, Jintao, Shang, Lei, Tan, Zhijun, Su, Haichuan, Zhang, Yingqi, Zhang, Cun, Li, Meng
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b563t-ca0b2ec778532fb6f926fd57f84ffd4a728550dbf67316db15f7d7c7dbb4f0903
cites cdi_FETCH-LOGICAL-b563t-ca0b2ec778532fb6f926fd57f84ffd4a728550dbf67316db15f7d7c7dbb4f0903
container_end_page
container_issue 9
container_start_page e002787
container_title Journal for immunotherapy of cancer
container_volume 9
creator Wang, Zhaowei
He, Lei
Li, Weina
Xu, Chuanyang
Zhang, Jieyu
Wang, Desheng
Dou, Kefeng
Zhuang, Ran
Jin, Boquan
Zhang, Wei
Hao, Qiang
Zhang, Kuo
Zhang, Wangqian
Wang, Shuning
Gao, Yuan
Gu, Jintao
Shang, Lei
Tan, Zhijun
Su, Haichuan
Zhang, Yingqi
Zhang, Cun
Li, Meng
description BackgroundA better understanding of the molecular mechanisms that manifest in the immunosuppressive tumor microenvironment (TME) is crucial for developing more efficacious immunotherapies for hepatocellular carcinoma (HCC), which has a poor response to current immunotherapies. Regulatory T (Treg) cells are key mediators of HCC-associated immunosuppression. We investigated the selective mechanism exploited by HCC that lead to Treg cells expansion and to find more efficacious immunotherapies.MethodsWe used matched tumor tissues and blood samples from 150 patients with HCC to identify key factors of Treg cells expansion. We used mass cytometry (CyTOF) and orthotopic cancer mouse models to analyze overall immunological changes after growth differentiation factor 15 (GDF15) gene ablation in HCC. We used flow cytometry, coimmunoprecipitation, RNA sequencing, mass spectrum, chromatin immunoprecipitation and Gdf15–/–, OT-I and GFP transgenic mice to demonstrate the effects of GDF15 on Treg cells and related molecular mechanism. We used hybridoma technology to generate monoclonal antibody to block GDF15 and evaluate its effects on HCC-associated immunosuppression.ResultsGDF15 is positively associated with the elevation of Treg cell frequencies in patients wih HCC. Gene ablation of GDF15 in HCC can convert an immunosuppressive TME to an inflammatory state. GDF15 promotes the generation of peripherally derived inducible Treg (iTreg) cells and enhances the suppressive function of natural Treg (nTreg) cells by interacting with a previously unrecognized receptor CD48 on T cells and thus downregulates STUB1, an E3 ligase that mediates forkhead box P3 (FOXP3) protein degradation. GDF15 neutralizing antibody effectively eradicates HCC and augments the antitumor immunity in mouse.ConclusionsOur results reveal the generation and function enhancement of Treg cells induced by GDF15 is a new mechanism for HCC-related immunosuppression. CD48 is the first discovered receptor of GDF15 in the immune system which provide the possibility to solve the molecular mechanism of the immunomodulatory function of GDF15. The therapeutic GDF15 blockade achieves HCC clearance without obvious adverse events.
doi_str_mv 10.1136/jitc-2021-002787
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d1b9165920ba4fccb35243b894017e8f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d1b9165920ba4fccb35243b894017e8f</doaj_id><sourcerecordid>2570110541</sourcerecordid><originalsourceid>FETCH-LOGICAL-b563t-ca0b2ec778532fb6f926fd57f84ffd4a728550dbf67316db15f7d7c7dbb4f0903</originalsourceid><addsrcrecordid>eNqNks1rFjEQxhdRbKm9e5IFL4Ku5nOTXAR5a2uh4KVevIR8vs2yu1mT3UL_e7NufW0FwVMmM795mEyeqnoJwXsIcfuhC7NpEECwAQAxzp5UxwhQ2ECC2qcP4qPqNOcOAAABxpzz59URJoQLjMlx9f3i7BzSOox2MS7XYRiWMeZlmpLLOcSxvg2q3p0RXpc4uf3Sqzmmu_q6Nq7vS8NY37ip5NZrKabaqGTCGAf1onrmVZ_d6f15Un07_3y9-9Jcfb243H26ajRt8dwYBTRyhjFOMfK69QK13lLmOfHeEsUQpxRY7VuGYWs1pJ5ZZpjVmnggAD6pLjddG1UnpxQGle5kVEH-SsS0lyrNwfROWqgFbKlAQCvijdGYIoI1FwRA5rgvWh83rWnRg7PGjXNS_SPRx5Ux3Mh9vJWcIEQ4LgJv7gVS_LG4PMsh5HU3anRxyRJRBiAElMCCvv4L7eKSxrKqQgncEgEFKRTYKJNizsn5wzAQyNUHcvWBXH0gNx-UllcPH3Fo-P3rBXi7AXro_kfu3R_6MOI_8Z90KMmn</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2593649194</pqid></control><display><type>article</type><title>GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma</title><source>Publicly Available Content (ProQuest)</source><source>PubMed</source><source>British Medical Journal Open Access Journals</source><creator>Wang, Zhaowei ; He, Lei ; Li, Weina ; Xu, Chuanyang ; Zhang, Jieyu ; Wang, Desheng ; Dou, Kefeng ; Zhuang, Ran ; Jin, Boquan ; Zhang, Wei ; Hao, Qiang ; Zhang, Kuo ; Zhang, Wangqian ; Wang, Shuning ; Gao, Yuan ; Gu, Jintao ; Shang, Lei ; Tan, Zhijun ; Su, Haichuan ; Zhang, Yingqi ; Zhang, Cun ; Li, Meng</creator><creatorcontrib>Wang, Zhaowei ; He, Lei ; Li, Weina ; Xu, Chuanyang ; Zhang, Jieyu ; Wang, Desheng ; Dou, Kefeng ; Zhuang, Ran ; Jin, Boquan ; Zhang, Wei ; Hao, Qiang ; Zhang, Kuo ; Zhang, Wangqian ; Wang, Shuning ; Gao, Yuan ; Gu, Jintao ; Shang, Lei ; Tan, Zhijun ; Su, Haichuan ; Zhang, Yingqi ; Zhang, Cun ; Li, Meng</creatorcontrib><description>BackgroundA better understanding of the molecular mechanisms that manifest in the immunosuppressive tumor microenvironment (TME) is crucial for developing more efficacious immunotherapies for hepatocellular carcinoma (HCC), which has a poor response to current immunotherapies. Regulatory T (Treg) cells are key mediators of HCC-associated immunosuppression. We investigated the selective mechanism exploited by HCC that lead to Treg cells expansion and to find more efficacious immunotherapies.MethodsWe used matched tumor tissues and blood samples from 150 patients with HCC to identify key factors of Treg cells expansion. We used mass cytometry (CyTOF) and orthotopic cancer mouse models to analyze overall immunological changes after growth differentiation factor 15 (GDF15) gene ablation in HCC. We used flow cytometry, coimmunoprecipitation, RNA sequencing, mass spectrum, chromatin immunoprecipitation and Gdf15–/–, OT-I and GFP transgenic mice to demonstrate the effects of GDF15 on Treg cells and related molecular mechanism. We used hybridoma technology to generate monoclonal antibody to block GDF15 and evaluate its effects on HCC-associated immunosuppression.ResultsGDF15 is positively associated with the elevation of Treg cell frequencies in patients wih HCC. Gene ablation of GDF15 in HCC can convert an immunosuppressive TME to an inflammatory state. GDF15 promotes the generation of peripherally derived inducible Treg (iTreg) cells and enhances the suppressive function of natural Treg (nTreg) cells by interacting with a previously unrecognized receptor CD48 on T cells and thus downregulates STUB1, an E3 ligase that mediates forkhead box P3 (FOXP3) protein degradation. GDF15 neutralizing antibody effectively eradicates HCC and augments the antitumor immunity in mouse.ConclusionsOur results reveal the generation and function enhancement of Treg cells induced by GDF15 is a new mechanism for HCC-related immunosuppression. CD48 is the first discovered receptor of GDF15 in the immune system which provide the possibility to solve the molecular mechanism of the immunomodulatory function of GDF15. The therapeutic GDF15 blockade achieves HCC clearance without obvious adverse events.</description><identifier>ISSN: 2051-1426</identifier><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1136/jitc-2021-002787</identifier><identifier>PMID: 34489334</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd</publisher><subject>Animals ; Basic Tumor Immunology ; biomarkers ; Cancer ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - immunology ; Carcinoma, Hepatocellular - pathology ; CD48 Antigen - immunology ; Clustering ; Genomes ; Growth Differentiation Factor 15 - immunology ; Humans ; Immune Tolerance ; Immunotherapy ; Liver cancer ; Liver Neoplasms - genetics ; Liver Neoplasms - immunology ; Liver Neoplasms - pathology ; Lymphatic system ; Lymphocytes ; Male ; Mice ; Physiology ; T-Lymphocytes, Regulatory - immunology ; tumor ; tumor escape ; tumor microenvironment ; Tumor Microenvironment - immunology ; Tumors</subject><ispartof>Journal for immunotherapy of cancer, 2021-09, Vol.9 (9), p.e002787</ispartof><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b563t-ca0b2ec778532fb6f926fd57f84ffd4a728550dbf67316db15f7d7c7dbb4f0903</citedby><cites>FETCH-LOGICAL-b563t-ca0b2ec778532fb6f926fd57f84ffd4a728550dbf67316db15f7d7c7dbb4f0903</cites><orcidid>0000-0002-8000-3003</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2593649194/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2593649194?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27528,27529,27903,27904,36991,36992,44569,53770,53772,55329,74873,77348,77379,77407,77433</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34489334$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Zhaowei</creatorcontrib><creatorcontrib>He, Lei</creatorcontrib><creatorcontrib>Li, Weina</creatorcontrib><creatorcontrib>Xu, Chuanyang</creatorcontrib><creatorcontrib>Zhang, Jieyu</creatorcontrib><creatorcontrib>Wang, Desheng</creatorcontrib><creatorcontrib>Dou, Kefeng</creatorcontrib><creatorcontrib>Zhuang, Ran</creatorcontrib><creatorcontrib>Jin, Boquan</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Hao, Qiang</creatorcontrib><creatorcontrib>Zhang, Kuo</creatorcontrib><creatorcontrib>Zhang, Wangqian</creatorcontrib><creatorcontrib>Wang, Shuning</creatorcontrib><creatorcontrib>Gao, Yuan</creatorcontrib><creatorcontrib>Gu, Jintao</creatorcontrib><creatorcontrib>Shang, Lei</creatorcontrib><creatorcontrib>Tan, Zhijun</creatorcontrib><creatorcontrib>Su, Haichuan</creatorcontrib><creatorcontrib>Zhang, Yingqi</creatorcontrib><creatorcontrib>Zhang, Cun</creatorcontrib><creatorcontrib>Li, Meng</creatorcontrib><title>GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma</title><title>Journal for immunotherapy of cancer</title><addtitle>J Immunother Cancer</addtitle><addtitle>J Immunother Cancer</addtitle><description>BackgroundA better understanding of the molecular mechanisms that manifest in the immunosuppressive tumor microenvironment (TME) is crucial for developing more efficacious immunotherapies for hepatocellular carcinoma (HCC), which has a poor response to current immunotherapies. Regulatory T (Treg) cells are key mediators of HCC-associated immunosuppression. We investigated the selective mechanism exploited by HCC that lead to Treg cells expansion and to find more efficacious immunotherapies.MethodsWe used matched tumor tissues and blood samples from 150 patients with HCC to identify key factors of Treg cells expansion. We used mass cytometry (CyTOF) and orthotopic cancer mouse models to analyze overall immunological changes after growth differentiation factor 15 (GDF15) gene ablation in HCC. We used flow cytometry, coimmunoprecipitation, RNA sequencing, mass spectrum, chromatin immunoprecipitation and Gdf15–/–, OT-I and GFP transgenic mice to demonstrate the effects of GDF15 on Treg cells and related molecular mechanism. We used hybridoma technology to generate monoclonal antibody to block GDF15 and evaluate its effects on HCC-associated immunosuppression.ResultsGDF15 is positively associated with the elevation of Treg cell frequencies in patients wih HCC. Gene ablation of GDF15 in HCC can convert an immunosuppressive TME to an inflammatory state. GDF15 promotes the generation of peripherally derived inducible Treg (iTreg) cells and enhances the suppressive function of natural Treg (nTreg) cells by interacting with a previously unrecognized receptor CD48 on T cells and thus downregulates STUB1, an E3 ligase that mediates forkhead box P3 (FOXP3) protein degradation. GDF15 neutralizing antibody effectively eradicates HCC and augments the antitumor immunity in mouse.ConclusionsOur results reveal the generation and function enhancement of Treg cells induced by GDF15 is a new mechanism for HCC-related immunosuppression. CD48 is the first discovered receptor of GDF15 in the immune system which provide the possibility to solve the molecular mechanism of the immunomodulatory function of GDF15. The therapeutic GDF15 blockade achieves HCC clearance without obvious adverse events.</description><subject>Animals</subject><subject>Basic Tumor Immunology</subject><subject>biomarkers</subject><subject>Cancer</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>CD48 Antigen - immunology</subject><subject>Clustering</subject><subject>Genomes</subject><subject>Growth Differentiation Factor 15 - immunology</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>Immunotherapy</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - immunology</subject><subject>Liver Neoplasms - pathology</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Mice</subject><subject>Physiology</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>tumor</subject><subject>tumor escape</subject><subject>tumor microenvironment</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumors</subject><issn>2051-1426</issn><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks1rFjEQxhdRbKm9e5IFL4Ku5nOTXAR5a2uh4KVevIR8vs2yu1mT3UL_e7NufW0FwVMmM795mEyeqnoJwXsIcfuhC7NpEECwAQAxzp5UxwhQ2ECC2qcP4qPqNOcOAAABxpzz59URJoQLjMlx9f3i7BzSOox2MS7XYRiWMeZlmpLLOcSxvg2q3p0RXpc4uf3Sqzmmu_q6Nq7vS8NY37ip5NZrKabaqGTCGAf1onrmVZ_d6f15Un07_3y9-9Jcfb243H26ajRt8dwYBTRyhjFOMfK69QK13lLmOfHeEsUQpxRY7VuGYWs1pJ5ZZpjVmnggAD6pLjddG1UnpxQGle5kVEH-SsS0lyrNwfROWqgFbKlAQCvijdGYIoI1FwRA5rgvWh83rWnRg7PGjXNS_SPRx5Ux3Mh9vJWcIEQ4LgJv7gVS_LG4PMsh5HU3anRxyRJRBiAElMCCvv4L7eKSxrKqQgncEgEFKRTYKJNizsn5wzAQyNUHcvWBXH0gNx-UllcPH3Fo-P3rBXi7AXro_kfu3R_6MOI_8Z90KMmn</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Wang, Zhaowei</creator><creator>He, Lei</creator><creator>Li, Weina</creator><creator>Xu, Chuanyang</creator><creator>Zhang, Jieyu</creator><creator>Wang, Desheng</creator><creator>Dou, Kefeng</creator><creator>Zhuang, Ran</creator><creator>Jin, Boquan</creator><creator>Zhang, Wei</creator><creator>Hao, Qiang</creator><creator>Zhang, Kuo</creator><creator>Zhang, Wangqian</creator><creator>Wang, Shuning</creator><creator>Gao, Yuan</creator><creator>Gu, Jintao</creator><creator>Shang, Lei</creator><creator>Tan, Zhijun</creator><creator>Su, Haichuan</creator><creator>Zhang, Yingqi</creator><creator>Zhang, Cun</creator><creator>Li, Meng</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8000-3003</orcidid></search><sort><creationdate>20210901</creationdate><title>GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma</title><author>Wang, Zhaowei ; He, Lei ; Li, Weina ; Xu, Chuanyang ; Zhang, Jieyu ; Wang, Desheng ; Dou, Kefeng ; Zhuang, Ran ; Jin, Boquan ; Zhang, Wei ; Hao, Qiang ; Zhang, Kuo ; Zhang, Wangqian ; Wang, Shuning ; Gao, Yuan ; Gu, Jintao ; Shang, Lei ; Tan, Zhijun ; Su, Haichuan ; Zhang, Yingqi ; Zhang, Cun ; Li, Meng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b563t-ca0b2ec778532fb6f926fd57f84ffd4a728550dbf67316db15f7d7c7dbb4f0903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Basic Tumor Immunology</topic><topic>biomarkers</topic><topic>Cancer</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>CD48 Antigen - immunology</topic><topic>Clustering</topic><topic>Genomes</topic><topic>Growth Differentiation Factor 15 - immunology</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>Immunotherapy</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - immunology</topic><topic>Liver Neoplasms - pathology</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Mice</topic><topic>Physiology</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>tumor</topic><topic>tumor escape</topic><topic>tumor microenvironment</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Zhaowei</creatorcontrib><creatorcontrib>He, Lei</creatorcontrib><creatorcontrib>Li, Weina</creatorcontrib><creatorcontrib>Xu, Chuanyang</creatorcontrib><creatorcontrib>Zhang, Jieyu</creatorcontrib><creatorcontrib>Wang, Desheng</creatorcontrib><creatorcontrib>Dou, Kefeng</creatorcontrib><creatorcontrib>Zhuang, Ran</creatorcontrib><creatorcontrib>Jin, Boquan</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Hao, Qiang</creatorcontrib><creatorcontrib>Zhang, Kuo</creatorcontrib><creatorcontrib>Zhang, Wangqian</creatorcontrib><creatorcontrib>Wang, Shuning</creatorcontrib><creatorcontrib>Gao, Yuan</creatorcontrib><creatorcontrib>Gu, Jintao</creatorcontrib><creatorcontrib>Shang, Lei</creatorcontrib><creatorcontrib>Tan, Zhijun</creatorcontrib><creatorcontrib>Su, Haichuan</creatorcontrib><creatorcontrib>Zhang, Yingqi</creatorcontrib><creatorcontrib>Zhang, Cun</creatorcontrib><creatorcontrib>Li, Meng</creatorcontrib><collection>British Medical Journal Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Zhaowei</au><au>He, Lei</au><au>Li, Weina</au><au>Xu, Chuanyang</au><au>Zhang, Jieyu</au><au>Wang, Desheng</au><au>Dou, Kefeng</au><au>Zhuang, Ran</au><au>Jin, Boquan</au><au>Zhang, Wei</au><au>Hao, Qiang</au><au>Zhang, Kuo</au><au>Zhang, Wangqian</au><au>Wang, Shuning</au><au>Gao, Yuan</au><au>Gu, Jintao</au><au>Shang, Lei</au><au>Tan, Zhijun</au><au>Su, Haichuan</au><au>Zhang, Yingqi</au><au>Zhang, Cun</au><au>Li, Meng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><stitle>J Immunother Cancer</stitle><addtitle>J Immunother Cancer</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>9</volume><issue>9</issue><spage>e002787</spage><pages>e002787-</pages><issn>2051-1426</issn><eissn>2051-1426</eissn><abstract>BackgroundA better understanding of the molecular mechanisms that manifest in the immunosuppressive tumor microenvironment (TME) is crucial for developing more efficacious immunotherapies for hepatocellular carcinoma (HCC), which has a poor response to current immunotherapies. Regulatory T (Treg) cells are key mediators of HCC-associated immunosuppression. We investigated the selective mechanism exploited by HCC that lead to Treg cells expansion and to find more efficacious immunotherapies.MethodsWe used matched tumor tissues and blood samples from 150 patients with HCC to identify key factors of Treg cells expansion. We used mass cytometry (CyTOF) and orthotopic cancer mouse models to analyze overall immunological changes after growth differentiation factor 15 (GDF15) gene ablation in HCC. We used flow cytometry, coimmunoprecipitation, RNA sequencing, mass spectrum, chromatin immunoprecipitation and Gdf15–/–, OT-I and GFP transgenic mice to demonstrate the effects of GDF15 on Treg cells and related molecular mechanism. We used hybridoma technology to generate monoclonal antibody to block GDF15 and evaluate its effects on HCC-associated immunosuppression.ResultsGDF15 is positively associated with the elevation of Treg cell frequencies in patients wih HCC. Gene ablation of GDF15 in HCC can convert an immunosuppressive TME to an inflammatory state. GDF15 promotes the generation of peripherally derived inducible Treg (iTreg) cells and enhances the suppressive function of natural Treg (nTreg) cells by interacting with a previously unrecognized receptor CD48 on T cells and thus downregulates STUB1, an E3 ligase that mediates forkhead box P3 (FOXP3) protein degradation. GDF15 neutralizing antibody effectively eradicates HCC and augments the antitumor immunity in mouse.ConclusionsOur results reveal the generation and function enhancement of Treg cells induced by GDF15 is a new mechanism for HCC-related immunosuppression. CD48 is the first discovered receptor of GDF15 in the immune system which provide the possibility to solve the molecular mechanism of the immunomodulatory function of GDF15. The therapeutic GDF15 blockade achieves HCC clearance without obvious adverse events.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd</pub><pmid>34489334</pmid><doi>10.1136/jitc-2021-002787</doi><orcidid>https://orcid.org/0000-0002-8000-3003</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2051-1426
ispartof Journal for immunotherapy of cancer, 2021-09, Vol.9 (9), p.e002787
issn 2051-1426
2051-1426
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d1b9165920ba4fccb35243b894017e8f
source Publicly Available Content (ProQuest); PubMed; British Medical Journal Open Access Journals
subjects Animals
Basic Tumor Immunology
biomarkers
Cancer
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - immunology
Carcinoma, Hepatocellular - pathology
CD48 Antigen - immunology
Clustering
Genomes
Growth Differentiation Factor 15 - immunology
Humans
Immune Tolerance
Immunotherapy
Liver cancer
Liver Neoplasms - genetics
Liver Neoplasms - immunology
Liver Neoplasms - pathology
Lymphatic system
Lymphocytes
Male
Mice
Physiology
T-Lymphocytes, Regulatory - immunology
tumor
tumor escape
tumor microenvironment
Tumor Microenvironment - immunology
Tumors
title GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A44%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GDF15%20induces%20immunosuppression%20via%20CD48%20on%20regulatory%20T%20cells%20in%20hepatocellular%20carcinoma&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Wang,%20Zhaowei&rft.date=2021-09-01&rft.volume=9&rft.issue=9&rft.spage=e002787&rft.pages=e002787-&rft.issn=2051-1426&rft.eissn=2051-1426&rft_id=info:doi/10.1136/jitc-2021-002787&rft_dat=%3Cproquest_doaj_%3E2570110541%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b563t-ca0b2ec778532fb6f926fd57f84ffd4a728550dbf67316db15f7d7c7dbb4f0903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2593649194&rft_id=info:pmid/34489334&rfr_iscdi=true